Stocks
NuCana plcNCNA
NASDAQHealthcareBiotechnology$1.03
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel nucleoside analog therapies for the treatment of cancer, with a lead candidate in Phase 2/3 trials for solid tumors. Investors track NuCana for its prodrug technology that aims to improve the efficacy and safety of established chemotherapy agents.
52W Range: $0.95-$4.55
Congressional Interest in NuCana plc (NCNA)
No congressional trades have been disclosed for NuCana plc (NCNA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NCNA?
No congressional trades found for this stock.